TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00881530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: BI 10773 high dose once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: open label comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: BI 10773 low dose once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: open label comparator
Study: NCT00924794

Intervention type: PROCEDURE
Intervention: Cancer Registry of Norway (database)
Description: Review of database to identify women with primary conization presenting with high grade lesions/ microinvasive cervical carcinomas. Recurrent cones with high grade lesions/ microinvasive cervical carcinomas or invasive cervical cancer will be identified for all women with primary cones.
Study: NCT00599352

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: magnesium
Description: Single infusion of elemental magnesium given over 4 hours, 0.2mEq/kg (2.4 mg/kg)
Study: NCT03686930

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cohort 1 - FP-045 oral solution
Description: FP-045 given orally with dose escalation between cohorts, based on emerging safety and pharmacokinetic (PK) data. Cohorts 2 and 3 doses to be based on the safety, tolerability, and PK data generated in the study. The dosing duration for cohorts 1-3 will be 7 consecutive days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cohort 2 - FP-045 oral solution
Description: FP-045 given orally with dose escalation between cohorts, based on emerging safety and pharmacokinetic (PK) data. Cohorts 2 and 3 doses to be based on the safety, tolerability, and PK data generated in the study. The dosing duration for cohorts 1-3 will be 7 consecutive days.
Study: NCT02384304

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Messages
Description: A self help program consisting of 8 modules and access to therapist guidance through messages
Study: NCT03686930

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cohort 3 - FP-045 oral solution
Description: FP-045 given orally with dose escalation between cohorts, based on emerging safety and pharmacokinetic (PK) data. Cohorts 2 and 3 doses to be based on the safety, tolerability, and PK data generated in the study. The dosing duration for cohorts 1-3 will be 7 consecutive days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for FP-045 oral solution)
Description: Participants (cohorts 1-3) will receive FP-045 oral solution matching placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for FP-045 oral solution)
Description: Participants (cohorts 1-3) will receive FP-045 oral solution matching placebo.
Study: NCT02384304

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self help
Description: A self help program consisting of 8 modules
Study: NCT03686930

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for FP-045 oral solution)
Description: Participants (cohorts 1-3) will receive FP-045 oral solution matching placebo.
Study: NCT00967057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given intrathecally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegaspargase
Description: Given intramuscularly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegaspargase
Description: Given intramuscularly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV
Study: NCT00851370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab (Xolair)
Description: Bi-weekly
Study: NCT01123031

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lansoprazole
Description: lansoprazole 30 mg four times daily for three days followed by 30 mg once daily for two months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: esomeprazole
Description: esomeprazole 160 mg/day continuous infusion for three days followed by 40 mg once daily orally for two months
Study: NCT04133662

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Manipulation Protocol
Description: A structured sleep duration intervention will be taught to patients

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Manipulation Protocol
Description: A structured sleep duration intervention will be taught to patients
Study: NCT02655276

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: microencapsulated Glycine
Description: 100 mg microencapsulated Glycine (Bidicin® from Biotiki® ) t.i.d.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: microencapsulated Glycine
Description: 100 mg microencapsulated Glycine (Bidicin® from Biotiki® ) t.i.d.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo tablets
Description: Placebo t.i.d. from Biotiki® in a crossover-design.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo tablets
Description: Placebo t.i.d. from Biotiki® in a crossover-design.
Study: NCT04556357

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: A maintenance dose of phenylephrine (0.625 μg/kg/min) infusion simultaneous with subarachnoid block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: A maintenance dose of norepinephrine (0.05 μg/kg/min) infusion simultaneous with subarachnoid block
Study: NCT02663427

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: serological examination and gastroscope

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: serological examination and gastroscope

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: serological examination and gastroscope

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: serological examination and gastroscope
Study: NCT02967419

Intervention type: OTHER
Intervention: No Intervention

Intervention type: OTHER
Intervention: No Intervention
Study: NCT00886327

Intervention type: PROCEDURE
Intervention: Colonic capsule endoscopy
Study: NCT00787839

Intervention type: OTHER
Intervention: Glucose challenge test
Description: At a first outpatient visit, at different times of the day and without a prior fast, subjects will have a 50 gram glucose drink followed by measurement of plasma and capillary glucose along with A1c one hour later. They will also fill out questionnaires. At a second outpatient visit, in the morning after fasting overnight, they will have a 75 gram oral glucose tolerance test.

Intervention type: OTHER
Intervention: Glucose tolerance test
Description: Subjects found to have diabetes or prediabetes on the initial glucose tolerance test may be requested to have a repeat glucose tolerance test and A1c.
Study: NCT00298298

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: L-Vax: Autologous, DNP-Modified NSCLC Vaccine
Description: autologous, DNP-modified NSCLC cells in suspension dosage - depends on arm route - intradermal frequency - weekly x7, booster at 6 months

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: L-Vax: Autologous, DNP-Modified NSCLC Vaccine
Description: autologous, DNP-modified NSCLC cells in suspension dosage - depends on arm route - intradermal frequency - weekly x7, booster at 6 months

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: L-Vax: Autologous, DNP-Modified NSCLC Vaccine
Description: autologous, DNP-modified NSCLC cells in suspension dosage - depends on arm route - intradermal frequency - weekly x7, booster at 6 months
Study: NCT02902445

Intervention type: BIOLOGICAL
Intervention: rotavirus rapid screen test
Description: According to routine care

Intervention type: GENETIC
Intervention: polymorphism exploration
Description: from an oral swab collected after parents consent

Intervention type: GENETIC
Intervention: polymorphism exploration
Description: from an oral swab collected after parents consent
Study: NCT02968498

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactulose crystals 10 g
Description: White or almost white crystalline powder used as food ingredient. The products will be provided in sachets to be dissolved in 250 mL water.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactulose crystals 20 g
Description: White or almost white crystalline powder used as food ingredient. The products will be provided in sachets to be dissolved in 250 mL water.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactulose liquid 10 g
Description: Clear, viscous liquid, colourless or pale brownish-yellow liquid syrup (solution). The products will be provided in sachets to be dissolved in 250 mL water.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactulose liquid 20 g
Description: Clear, viscous liquid, colourless or pale brownish-yellow liquid syrup (solution). The products will be provided in sachets to be dissolved in 250 mL water.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oral glucose 20 g
Description: White crystalline powder used as food ingredient. To standardise for 20 g glucose, 22 g glucose monohydrate will be used. The products will be provided in sachets to be dissolved in 250 mL water.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oral glucose 20 g
Description: White crystalline powder used as food ingredient. To standardise for 20 g glucose, 22 g glucose monohydrate will be used. The products will be provided in sachets to be dissolved in 250 mL water.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Still water
Description: Still water will be used. Water from the same source will be also used to dissolve investigational and control products.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Still water
Description: Still water will be used. Water from the same source will be also used to dissolve investigational and control products.
Study: NCT00851370

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Bi-Weekly
Study: NCT00289783

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis 792014 vaccine
Description: 3-dose intramuscular injection at 2, 4 and 6 months of age, and 1 booster dose by intramuscular injection at 12 to 15 months of age.
Study: NCT02385903

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flammacerium

Intervention type: OTHER
Group type: OTHER
Intervention: Standard dressing procedure
Study: NCT01735734

Intervention type: DEVICE
Intervention: Air cooling to CM site
Study: NCT05793359

Intervention type: DRUG
Intervention: Methylprednisolone
Description: methylprednisolone applied as intravenous infusions or intramuscularly

Intervention type: DRUG
Intervention: Methylprednisolone
Description: methylprednisolone applied as intravenous infusions or intramuscularly
Study: NCT03102450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzalkonium Chloride Spermicide Cream
Description: One dose of Pharmatex vaginal cream (benzalkonium chloride) must be used systematically before each intercourse, regardless of the cycle period, even during menstrual periods. In case of repeated acts of intercourse, an additional dose of cream must be used before each new act.~Duration of treatment : 6 months (12 months optional)
Study: NCT04358146

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Infant formula
Description: Exclusive formula feeding with the new infant formula thickened with fibers

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Infant formula thickened with locust bean gum
Description: Exclusive formula feeding with the formula thickened with locust bean
Study: NCT02688270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vascana (0.9% nitroglycerin cream)
Description: Study drug administered topically

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vascana (0.9% nitroglycerin cream)
Description: Study drug administered topically

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vascana (0.9% nitroglycerin cream)
Description: Study drug administered topically

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vascana (0.9% nitroglycerin cream)
Description: Study drug administered topically

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle Cream (placebo)
Description: Vehicle administered topically

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle Cream (placebo)
Description: Vehicle administered topically

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle Cream (placebo)
Description: Vehicle administered topically

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle Cream (placebo)
Description: Vehicle administered topically
Study: NCT01754246

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 755nm Alexandrite Laser
Description: 755nm Alexandrite laser for treatment of epidermal pigmented lesions and skin toning in Asian skin types

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 755nm Alexandrite Laser
Description: 755nm Alexandrite laser for treatment of epidermal pigmented lesions and skin toning in Asian skin types
Study: NCT05096143

Intervention type: DRUG
Intervention: Sacubitril/valsartan
Description: Participants who were prescribed with Sacubitril/valsartan

Intervention type: DRUG
Intervention: ACEi/ARB
Description: Participants who were prescribed with Angiotensin-converting enzyme inhibitors/Angiotensin II receptor antagonists (ACEi/ARB)
Study: NCT03472495

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diltiazem Oral Product
Description: Diltiazem Immediate Release 60 MG PO Q6H (30 MG PO Q6H if patient is \<60 kg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diltiazem Injectable Product
Description: Diltiazem Continuous Infusion Titrated
Study: NCT03807050

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Astaxanthin
Description: Capsules containing astaxanthin derived from the yeast Phaffia rhodozyma .
Study: NCT00749788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTT-302
Description: JTT-302, 100 mg tablets, 200 mg dose, oral, 30 minutes after the start of the morning meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTT-302
Description: JTT-302, 100 mg tablets, 400 mg dose, oral, 30 minutes after the start of the morning meal

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets, oral, 30 minutes after the start of the morning meal
Study: NCT04784793

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: App-based group
Description: Participants received home exercise programs by a postural alignment exercise mobile app we developed.~The postural alignment app included 3 main emerged themes were recorded as self-assessment, neck/shoulder, and upper back-specific exercise content, and motivational notifications.~Participants can evaluate themselves in the application thanks to the self-assessment, receive motivational notifications during the day, and exercise reminders on the days determined by them. They can apply the exercise program with the formed exercise content videos.~The exercise program consists of combined exercises that postural alignment plus exercises of neck spinal stabilization, stretching, and strengthening of neck/shoulders/upper back regions.~Both group participants were requested to do the exercises from the app/brochure 3 times a week, for 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control group
Description: Participants received home exercise programs as a paper handout.~The exercise program was the same for app-based and control groups.~Both group participants were requested to do the exercises from the app/brochure 3 times a week, for 6 weeks.
Study: NCT03930771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1500mg/m2 orally per day (divided into two doses with maximum daily dose of 2500mg) on days 1 through 14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 150 to 200 mg/m2 orally on days 10 through 14.
Study: NCT00057759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildenafil citrate

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02285504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-547
Description: Intravenous injection
Study: NCT01042938

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Curcumin C3 Complex
Description: Patients take 2.0 grams curcumin (four 500mg capsules) three times daily by mouth for prescribed course of radiation treatment (\~4-7 weeks)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients take 2.0 grams placebo (four 500mg capsules) three times daily by mouth for prescribed course of radiation treatment (\~4-7 weeks)
Study: NCT02520388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLD200 methylphenidate hydrochloride (MPH) Capsules
Description: HLD200 Doses: 40, 60 or 80 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04560686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bintrafusp Alfa
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study: NCT02445014

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MGH SECM Imaging Capsule
Description: Imaging of the Esophagus using the SECM capsule and SECM Imaging system
Study: NCT03506412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entresto™ 49Mg-51 mg tablet
Description: Entresto™ 49Mg-51 mg will be given twice daily orally for 5 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entresto™ 49Mg-51 mg tablet
Description: Entresto™ 49Mg-51 mg will be given twice daily orally for 5 weeks
Study: NCT00260832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine or Supportive Care
Description: Patient's choice with physician's advice of either supportive care (IV fluids, nutrition, and antibiotics as needed) or cytarabine 20 mg/m\^2 subcutaneously once daily for the first 10 consecutive days of each 28 day cycle, until progression or unacceptable toxicity develops. (These represent one intervention.)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dacogen (decitabine) only
Description: 20mg/m\^2, 1 hour intravenous (IV) for 5 consecutive days of each 28 day cycle. Cycles continue until disease progression or unacceptable toxicity develops.
Study: NCT02594228

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Whey Protein and exercise training
Description: Six meals per day four of which were whole food and two of whey protein for an overall percentage of macronutrient intake of 25% protein and 4 days per week of exercise training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food Protein and exercise training
Description: Six meals per day all of which were whole food protein for an overall percentage of macronutrient intake of 25% protein and 4 days per week of exercise training
Study: NCT01143909

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: omitting FFP transfusion before an intervention
Description: In the interventional group FFP transfusion is omitted before performing a procedure (e.g. placement of central venous catheter, tracheostomy, chest tube)
Study: NCT00119236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tanespimycin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Study: NCT03282344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-214
Description: 0.006mg/kg IV on day 1 and every 3 weeks thereafter will be an intravenous (IV) infusion administered over 30 (±5) minutes every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-214
Description: 0.006mg/kg IV on day 1 and every 3 weeks thereafter will be an intravenous (IV) infusion administered over 30 (±5) minutes every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 360mg (flat dose) IV infusion administered over 30 (±5) minutes every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 360mg (flat dose) IV infusion administered over 30 (±5) minutes every 3 weeks.
Study: NCT02018523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: lenalidomide 10mg/day orally until disease progression
Study: NCT00255723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: Given IV
Study: NCT02846792

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plinabulin
Description: Given IV
Study: NCT01308255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Prior to week 26~* Infliximab 3mg/kg standard regime (weeks 0, 2, 6, 14, 22)~* Methotrexate commencing at 10mg weekly, progressing to 20mg by week 6.~* Folic acid 5 mg daily except the day methotrexate is taken~Patients will be unblinded at week 26 and then treated pragmatically guided by disease activity

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylprednisolone
Description: Steroid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: All patients enrolled are commenced on oral methotrexate 10mg once a week The methotrexate dose should be increased to 15 mg at the week 2 visit. The methotrexate should be increased to 20mg at the week 6 visit.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: All patients enrolled are commenced on oral methotrexate 10mg once a week The methotrexate dose should be increased to 15 mg at the week 2 visit. The methotrexate should be increased to 20mg at the week 6 visit.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic acid
Description: All patients enrolled are commenced on oral folic acid 5mg daily, except the day methotrexate is taken, and the study infusions.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Folic acid
Description: All patients enrolled are commenced on oral folic acid 5mg daily, except the day methotrexate is taken, and the study infusions.
Study: NCT02749201

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gastrisail
Description: Light Intensity and gastric wall thickness assessment